Recursos COVID-19

Développer des compétences cliniques pour le Tester-pour-traiter, y compris l'identification des patients suspects de COVID-19, le triage, l'IPC, les tests de diagnostic rapide et les options de gestion/traitement. Ce programme a été développé par FHI 360 avec le soutien de l'USAID. Le cours est accessible au public gratuitement sur la plateforme EpiC Learns LMS (www.academy.fhi360.org/epic) en francés.

Desarrolle habilidades clínicas para Prueba-para-Tratar, incluida la identificación de pacientes con sospecha de COVID-19, triaje, prevención y control de infecciones (PCI), pruebas de diagnóstico rápido y opciones de atención/tratamiento. Este currículo fue desarrollado por FHI 360 con el apoyo de USAID. El curso está disponible al público de forma gratuita en la plataforma EpiC Learns LMS (www.academy.fhi360.org/epic) en español.

Développer des compétences cliniques pour le Tester-pour-traiter, y compris l'identification des patients suspects de COVID-19, le triage, l'IPC, les tests de diagnostic rapide et les options de gestion/traitement. Ce programme a été développé par FHI 360 avec le soutien de l'USAID. Le cours est accessible au public gratuitement sur la plateforme EpiC Learns LMS (www.academy.fhi360.org/epic) en francés.

Test-to-Treat for COVID-19 is an online, self-paced learning module to build clinical skills for T2T, including identification of patients with suspected COVID-19, triage, IPC, rapid diagnostic testing and management/treatment options.​ The target audience is frontline healthcare workers who may encounter patients with symptoms consistent with possible COVID-19​. The course is available to the public for free on the EpiC Learns LMS platform (www.academy.fhi360.org/epic) in English.

This PDSA Tool (Plan, Do, Study, Act) was created by RISE to aid in the implementation of Test-to-Treat programs, and serves as a template for other locations undergoing similar activities.

This FAQ provides answers to frequently asked questions about the COVID-19 Test to Treat strategy for clinicians, prescribers and health care teams.

This document provides answers to frequently asked questions about the COVID-19 Test to Treat strategy for clinicians, prescribers and health care teams.
An interactive version of the latest FAQ is also available via the link below.

Information for clinicians on mechanism of action for Molnupiravir, contraindications & indications, general dosage guidelines

Information for clinicians on mechanism of action for Paxlovid, contraindications & indications, general dosage guidelines.

Brief overview of the Test-to-Treat activity, answers key questions on purpose and target population

Information on purpose and use of self-tests in various environments.

Check out our OCC Job Aid Builder Tool for more free content to make your own job aid. Topics include respiratory care, emergency algorithms, critical care medications, procedures with more topics and more languages coming soon.

This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.

Two-page information sheet designed for patients who are taking molnupiravir. It is intended to be printed double-sided and folded in half.

Two-page information sheet designed for patients who are taking Paxlovid. It is intended to be printed double-sided and folded in half

This slide deck covers topics such as triage, testing and clinical management of COVID-19, including treatment with oral antiviral therapy.
This facilitator guide accompanies the slide deck and includes a script for the facilitator to teach this topic.

This calculator allows users to estimate the number of courses of oral antivirals that might be required during a calendar period, based on infection rate inputs.

Guidelines on COVID-19 Test to Treat, by the Africa Centres for Disease Control and Prevention (Guidance to Africa Union Member States)

Cet algorithme et ce guide de mise en œuvre sont destinés à aider les cliniciens au point de service à initier un traitement antiviral oral pour la COVID-19. Sur la base des données, le nirmatrelvir/ritonavir (NMV/r) est l'agent préféré, suivi du molnupiravir.

Ces ressources ont été créées par les partenaires EpIC, RISE, STAR-UCSF.